Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Data Supplement
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Knecht, H.
Right arrow Articles by Steck, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Knecht, H.
Right arrow Articles by Steck, A.
Related Collections
Right arrow Hematologic
Right arrow Chronic inflammatory demyelinating polyneuropathy
Right arrow All Clinical trials
Right arrow All Cognitive Disorders/Dementia
NEUROLOGY 2004;63:730-732
© 2004 American Academy of Neurology
Brief Communications

Sustained remission of CIDP associated with Evans syndrome

Hans Knecht, MD, Michael Baumberger, MD, Aurelio Tobòn, MD and Andreas Steck, MD

From the Institute for Clinical Research (Dr. Knecht) and Medical Clinic (Drs. Baumberger and Tobòn), Swiss Paraplegic Center, Nottwil, Switzerland; and Department of Neurology (Dr. Steck), University Hospital, Basel, Switzerland.

Address correspondence and reprint requests to Dr. Hans Knecht, Institute for Clinical Research, Swiss Paraplegic Centre, CH-6207 Nottwil (Lucerne), Switzerland; e-mail: hans.knecht{at}paranet.ch

A patient with chronic inflammatory demyelinating polyneuropathy (CIDP) developed Evans syndrome (hemolytic anemia/thrombocytopenia) 17 months after onset of symptoms despite different immunomodulatory treatments. A therapeutic approach with the chimeric monoclonal anti-CD20 antibody rituximab induced substantial improvement of CIDP and hematologic recovery. The patient remains in sustained remission 17 months after completion of therapy. Rituximab may represent a successful therapy in otherwise refractory CIDP.

Received February 9, 2004. Accepted in final form April 14, 2004.

Additional material related to this article can be found on the Neurology Web site. Go to www.neurology.org and scroll down the Table of Contents for the August 24 issue to find the title link for this article.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2004 by AAN Enterprises, Inc.